Literature DB >> 34338390

The novel KIT exon 11 germline mutation K558N is associated with gastrointestinal stromal tumor, mastocytosis, and seminoma development.

Michael Meir1, Katja Maurus2, Jochen Kuper3, Mohammed Hankir1, Eva Wardelmann4, Andreas Rosenwald2, Christoph-Thomas Germer1,5, Armin Wiegering1,5,6.   

Abstract

Familial gastrointestinal stromal tumors (GIST) are dominant genetic disorders that are caused by germline mutations of the type III receptor tyrosine kinase KIT. While sporadic mutations are frequently found in mastocytosis and GISTs, germline mutations of KIT have only been described in 39 families until now. We detected a novel germline mutation of KIT in exon 11 (p.Lys-558-Asn; K558N) in a patient from a kindred with several GISTs harboring different secondary somatic KIT mutations. Structural analysis suggests that the primary germline mutation alone is not sufficient to release the autoinhibitory region of KIT located in the transmembrane domain. Instead, the KIT kinase module becomes constitutively activated when K558N combines with different secondary somatic mutations. The identical germline mutation in combination with an additional somatic KIT mutation was detected in a second patient of the kindred with seminoma while a third patient within the family had a cutaneous mastocytosis. These findings suggest that the K558N mutation interferes with the juxtamembranous part of KIT, since seminoma and mastocystosis are usually not associated with exon 11 mutations.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  GIST; KIT; germline mutation; mastocytosis; seminoma

Mesh:

Substances:

Year:  2021        PMID: 34338390     DOI: 10.1002/gcc.22988

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  1 in total

1.  Patient-Derived Organoid Facilitating Personalized Medicine in Gastrointestinal Stromal Tumor With Liver Metastasis: A Case Report.

Authors:  Ying Cao; Xi Zhang; Qianyun Chen; Xi Rao; Enming Qiu; Gang Wu; Yu Lin; Ziqi Zeng; Bin Zheng; Zhou Li; Zhai Cai; Huaiming Wang; Shuai Han
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.